Metastatic atypical renal tumour with metanephric characteristics treated with Sunitinib

Research output: Contribution to journal › Journal article › Research › peer-review

Standard

Metastatic atypical renal tumour with metanephric characteristics treated with Sunitinib. / Mohammad, H.; Madsen, K.; Graumann, O.; Loya, A. C.; Jensen, N.; Dahlrot, R. H.

In: Urology Case Reports, Vol. 40, 101880, 2022.

Research output: Contribution to journal › Journal article › Research › peer-review

Harvard

Mohammad, H, Madsen, K, Graumann, O, Loya, AC, Jensen, N & Dahlrot, RH 2022, 'Metastatic atypical renal tumour with metanephric characteristics treated with Sunitinib', Urology Case Reports, vol. 40, 101880. https://doi.org/10.1016/j.eucr.2021.101880

APA

Mohammad, H., Madsen, K., Graumann, O., Loya, A. C., Jensen, N., & Dahlrot, R. H. (2022). Metastatic atypical renal tumour with metanephric characteristics treated with Sunitinib. Urology Case Reports, 40, [101880]. https://doi.org/10.1016/j.eucr.2021.101880

Vancouver

Mohammad H, Madsen K, Graumann O, Loya AC, Jensen N, Dahlrot RH. Metastatic atypical renal tumour with metanephric characteristics treated with Sunitinib. Urology Case Reports. 2022;40. 101880. https://doi.org/10.1016/j.eucr.2021.101880

Author

Mohammad, H. ; Madsen, K. ; Graumann, O. ; Loya, A. C. ; Jensen, N. ; Dahlrot, R. H. / Metastatic atypical renal tumour with metanephric characteristics treated with Sunitinib. In: Urology Case Reports. 2022 ; Vol. 40.

Bibtex

@article{afe1a29b04ed4babba53ebc8129cc171,

title = "Metastatic atypical renal tumour with metanephric characteristics treated with Sunitinib",

abstract = "Metanephric Adenoma (MA) is a rare and unclassifiable renal tumour with sparse reported clinical and morphological features. Generally MA's have a benign course without recurrence after nephrectomy, however a few cases received oncological treatment due to malignant progression. We present a 42-year-old woman who years after an initial nephrectomy developed several processes and biopsy confirmed recurrence of MA. Sunitinib was given for only two weeks, as she developed side-effects and currently the patient undergoes control scans with only minimal growth of the processes. This is the first case of MA treated with Tyrosin-Kinase-Inhibitor.",

keywords = "Metanephric adenoma, Tyrosine kinase inhibitor, Oncology, Renal tumour, ADENOMA",

author = "H. Mohammad and K. Madsen and O. Graumann and Loya, {A. C.} and N. Jensen and Dahlrot, {R. H.}",

year = "2022",

doi = "10.1016/j.eucr.2021.101880",

language = "English",

volume = "40",

journal = "Urology Case Reports",

issn = "2214-4420",

publisher = "Elsevier Saunders",

}

RIS

TY - JOUR

T1 - Metastatic atypical renal tumour with metanephric characteristics treated with Sunitinib

AU - Mohammad, H.

AU - Madsen, K.

AU - Graumann, O.

AU - Loya, A. C.

AU - Jensen, N.

AU - Dahlrot, R. H.

PY - 2022

Y1 - 2022

N2 - Metanephric Adenoma (MA) is a rare and unclassifiable renal tumour with sparse reported clinical and morphological features. Generally MA's have a benign course without recurrence after nephrectomy, however a few cases received oncological treatment due to malignant progression. We present a 42-year-old woman who years after an initial nephrectomy developed several processes and biopsy confirmed recurrence of MA. Sunitinib was given for only two weeks, as she developed side-effects and currently the patient undergoes control scans with only minimal growth of the processes. This is the first case of MA treated with Tyrosin-Kinase-Inhibitor.

AB - Metanephric Adenoma (MA) is a rare and unclassifiable renal tumour with sparse reported clinical and morphological features. Generally MA's have a benign course without recurrence after nephrectomy, however a few cases received oncological treatment due to malignant progression. We present a 42-year-old woman who years after an initial nephrectomy developed several processes and biopsy confirmed recurrence of MA. Sunitinib was given for only two weeks, as she developed side-effects and currently the patient undergoes control scans with only minimal growth of the processes. This is the first case of MA treated with Tyrosin-Kinase-Inhibitor.

KW - Metanephric adenoma

KW - Tyrosine kinase inhibitor

KW - Oncology

KW - Renal tumour

KW - ADENOMA

U2 - 10.1016/j.eucr.2021.101880

DO - 10.1016/j.eucr.2021.101880

M3 - Journal article

C2 - 34692420

VL - 40

JO - Urology Case Reports

JF - Urology Case Reports

SN - 2214-4420

M1 - 101880

ER -

ID: 290109540